Skip to main content
SpringerLink
Log in

Minder hartfalen door gebruik van chloortalidon bij hypertensie

  • Farmacotherapie
  • Published:
Medisch-Farmaceutische Mededelingen

Samenvatting

Het ALLHAT-onderzoek (The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial) had als doel vast te stellen welke eerste stap in de antihypertensieve behandeling de incidentie van coronaire hartziekten (CHZ) of andere cardiovasculaire aandoeningen het meest verlaagt. De behandeling met het langwerkend thiazideachtig diureticum chloortalidon werd vergeleken met de calciumantagonist amlodipine, de ACE-remmer lisinopril of de α-blokker doxazosine. Het is een gerandomiseerd, prospectief, dubbelblind en gecontroleerd onderzoek georganiseerd door het Amerikaanse National Heart, Lung, and Blood Institute. De 33.357 deelnemers waren 55 jaar of ouder, hadden hypertensie en ten minste één andere risicofactor voor coronaire hartziekten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomised to angiotensine-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

  2. Appel U.The verdict from ALLHAT-Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002;288:3039-42.

  3. Appel U.The verdict from ALLHAT-Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002;288:3039-42.

  4. Williams B. Drug treatment of hypertension. BMJ 2003;326: 61-2.

  5. Wing LMH, Reid CM, Ryan P, Beilin LI, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003348:583-92.

  6. Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ 2003;3260156-7.

Author information

Authors and Affiliations

  1. www.bsl.nl/shop/

    M. M. Toll

Authors
  1. M. M. Toll
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomised to angiotensine-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toll, M.M. Minder hartfalen door gebruik van chloortalidon bij hypertensie. MFAM 42, 30–31 (2004). https://doi.org/10.1007/BF03058316

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03058316

Search

Navigation